Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS
Article Abstract:
A tablet form of the AIDS drug didanosine (ddI) may be just as effective as a previously used sachet form of the drug. Researchers analyzed the differences in absorption into the blood of the tablet and sachet forms of ddI in 15 AIDS patients. The tablet form was better absorbed into the blood than was the sachet form, and the lower dosage of the tablets was as effective as the higher dose sachets. Patients with low body weights of less than 60 kg were given lower doses of ddI to match their low weight. They experienced low plasma levels of ddI, so ddI dosage may need to have a lower limit of 60 kg of body weight. The tablet form of ddI was created to increase patient acceptance and absorption into the blood.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Inhibition of murine AIDS by a new azidothymidine homodinucleotide
Article Abstract:
A new form of the AIDS drug AZT that is designed to protect blood cells called macrophages appears to be effective in treating HIV infection. The drug azidothymidine homodinucleotide was given to mice infected with a virus that produces a disease in mice similar to AIDS. The drug lowered viral levels in lymph nodes, spleen and brain and when combined with AZT was more effective than either drug alone in reducing viral levels in the brain. Unlike AZT, the drug did not adversely affect bone marrow.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients
Article Abstract:
Ritonavir and didanosine (ddI) only interact moderately when given concurrently in the treatment of HIV infection, so dosage adjustments during simultaneous administration may not be necessary. Researchers tested 6 dosage and administration protocols for concurrent use of the antiviral medications, and saw no significant pharmacokinetic changes. Concurrent administration caused ritonavir concentrations in the blood to rise less than 10% and didanosine concentrations to fall about 15%.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Education and accountability. Drugs administration keeping pace with change. Self-administration of drugs: an introduction
- Abstracts: Nurse-led diabetes clinics benefit black and Asian patients. Diabetes: medical complications
- Abstracts: Audit of nutrition screening in patients with acute illness. View from the independent acute health-care sector
- Abstracts: Potential effects of managed care on specialty practice at a university medical center. Trends in health care coverage and financing and their implications for policy
- Abstracts: Long-term outcome of Haemophilus influenzae meningitis in Navajo Indian children. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era